China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total output and vitamin E takes up about 30%. Since 2009, influenced by the sluggish external demand and declining prices, China's output of vitamin products has been declining sharply. In 2013, the output of various types of vitamin products in China was about 201,000 tons, down 7.4% YoY.
Browse Full Report With TOC: http://www.marketresearchreports.biz/analysis-details/china-vitamin-industry-report2014-2017
China is also the world's largest export base of vitamins, mainly vitamin C, vitamin E and pantothenic calcium. In 2013, China's export volume of vitamin C and vitamin E accounted for 55.0% and 23.7% of total export volume over the same period. In addition, the proportions of D or DL-pantothenic acid (i.e. vitamin B3 or B5) have increased to 5.7%.
Chinese vitamin producers fall into two types: large integrated pharmaceutical enterprises and professional vitamin producers. In 2009-2013, large integrated pharmaceutical enterprises such as North China Pharmaceutical Co.,Ltd and Northeast Pharmaceutical Group Co.,Ltd mostly had heavy burden historically and encountered operating difficulties and development obstacles, thus their ratio of R & D investment in total revenue was less than 3%; while professional vitamin producers like NHU, Kingdomway, and Brother Enterprises Holding kept higher gross margins of their products, with R & D investment generally accounting for more than 4% of revenue.
To Download Full Report with TOC: http://www.marketresearchreports.biz/sample/sample/206802
In recent years, the global and Chinese vitamin market has been exhibiting a monopolistic competition pattern. CSPC Pharmaceutical Group, North China Pharmaceutical, Northeast Pharmaceutical, Aland (Jiangsu) Nutraceutical, Shandong Luwei Pharmaceutical and other Chinese companies with production capacity of more than 15,000 tons, are the major suppliers in the global VC market. Zhejiang Medicine, NHU, and PKU Healthcare together shared about 50% of the global total capacity of VE. NHU, Zhejiang Medicine and Kingdomway three companies together accounted for 40%-50% of the global total capacity of VA.
Since the vitamin industry has high technical barriers, the existing major producers have already formed their own competitive advantages and the cost of quitting is high. So it is estimated that in 2014-2017, the monopolistic competition pattern in China vitamin industry will persist.
To Read Complete Report with TOC: http://www.marketresearchreports.biz/analysis/206802
Table of Content
1 Overview of Vitamins
1.3 Global Overview
2 Development of China Vitamin Industry
2.1 Status Quo
2.2 Import and Export
2.3 Competition Pattern
3 China Vitamin Market Segments
3.1.1 Development Status
3.1.2 Import and Export
3.1.3 Market Price
3.2.1 D or DL-Pantothenic Acid (Vitamin B3 or Vitamin B5)
Office: United States
90 State Street, Suite 700
Albany, NY 12207
Toll Free: 866-997-4948